- Conditions
- Transgenderism, Kidney Diseases, Kidney Injury
- Interventions
- p-aminohippurate clearance study, Iohexol infusion
- Diagnostic Test
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 17 Years to 30 Years
- Enrollment
- 22 participants
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1201–1224
of 7,459
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neoplasms
- Interventions
- Regorafenib (Stivarga, BAY73-4506)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Aurora, Colorado • St Louis, Missouri + 2 more
- Conditions
- Urinary Bladder, Overactive
- Interventions
- solifenacin succinate
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 441 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 104
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 90 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Breast Neoplasms, Urinary Bladder Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Colorectal Neoplasms, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Interventions
- SGN-2FF, pembrolizumab
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Duarte, California • Aurora, Colorado + 8 more
- Conditions
- Elevated Alanine Transaminase (ALT)
- Interventions
- Tasso+ SST
- Other
- Lead sponsor
- Tasso Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • New York, New York • Kirkland, Washington
- Conditions
- Neoplasms
- Interventions
- Gene-modified (GM) T cell therapy
- Genetic
- Lead sponsor
- Celgene
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2043
- U.S. locations
- 104
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 75 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, Pegasys, RO5024048, danoprevir, ritonavir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 19
- States / cities
- La Jolla, California • Long Beach, California • Sacramento, California + 15 more
- Conditions
- Multiple Sclerosis
- Interventions
- Low-Load Exercise with Blood Flow Restriction, Low-Load Exercise Control Group
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Haemophilia A, Haemophilia A With Inhibitors
- Interventions
- NNC0365-3769 (Mim8) PPX
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Sacramento, California • Aurora, Colorado + 10 more
- Conditions
- Urothelial Carcinoma
- Interventions
- Erdafitinib, Cetrelimab, Cisplatin, Carboplatin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 12
- States / cities
- Aurora, Colorado • Louisville, Kentucky • Rockville, Maryland + 9 more
- Conditions
- Polycystic Kidney, Autosomal Dominant
- Interventions
- Empagliflozin, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Life Style
- Interventions
- Health Links + Leadership Training, Health Links
- Behavioral
- Lead sponsor
- Colorado School of Public Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,175 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery
- Interventions
- Thoracic, Abdominal, Custom Device, Illiac Artery
- Device
- Lead sponsor
- Vascutek Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 17
- States / cities
- Long Beach, California • Aurora, Colorado • Colorado Springs, Colorado + 14 more
- Conditions
- Sarcopenia
- Interventions
- REGN1033 (SAR391786), placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 70 Years and older
- Enrollment
- 253 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 33
- States / cities
- Anniston, Alabama • Phoenix, Arizona • El Cajon, California + 30 more
- Conditions
- HIV-1
- Interventions
- Maraviroc + Zidovudine/Lamivudine, Efavirenz + Zidovudine/Lamivudine, Maraviroc (UK-427,857) + Zidovudine/Lamivudine
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 916 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 33 more
- Conditions
- Atopic Dermatitis, Type 1 Hypersensitivity
- Interventions
- STMC-103H, Placebo
- Biological
- Lead sponsor
- Siolta Therapeutics, Inc.
- Industry
- Eligibility
- 0 Days to 14 Days
- Enrollment
- 283 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
- Conditions
- Tricuspid Regurgitation
- Interventions
- TriClipTM Device
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more
- Conditions
- Primary Pulmonary Hypertension
- Interventions
- LIQ861 Inhaled Treprostinil
- Drug
- Lead sponsor
- Liquidia Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
- Conditions
- Advanced or Metastatic Breast Cancer
- Interventions
- Trastuzumab deruxtecan, Capecitabine, Paclitaxel, Nab-Paclitaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 105 Years
- Enrollment
- 866 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 27
- States / cities
- Scottsdale, Arizona • Springdale, Arkansas • Duarte, California + 23 more
- Conditions
- COVID-19 Testing
- Interventions
- Not listed
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,235 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Advanced Solid Tumor, Gynecologic Cancer
- Interventions
- Lucitanib, Nivolumab
- Drug
- Lead sponsor
- Clovis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Diego, California • Aurora, Colorado + 9 more
- Conditions
- Fragile X Syndrome
- Interventions
- arbaclofen
- Drug
- Lead sponsor
- Seaside Therapeutics, Inc.
- Industry
- Eligibility
- 5 Years to 50 Years
- Enrollment
- 357 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Long Beach, California • Sacramento, California + 20 more
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage III Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
- Interventions
- Filgrastim, Laboratory Biomarker Analysis, Pegfilgrastim, Topotecan Hydrochloride, Veliparib
- Biological · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 78
- States / cities
- Orange, California • Aurora, Colorado • Hartford, Connecticut + 56 more
- Conditions
- Heart Failure, Left Ventricular Systolic Dysfunction
- Interventions
- Vericiguat tablet, Vericiguat suspension, Placebo tablet, Placebo suspension
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 29 Days to 17 Years
- Enrollment
- 342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Palo Alto, California • San Bernardino, California + 17 more